Pregabalin Capsule
Product Images NDC 82804-300

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-300). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Pregabalin 75 mg capsules label from Proficient Rx LP. The label indicates a 60-capsule package, each capsule containing 75 mg pregabalin in an orange/white hard gelatin capsule with black ink print. The manufacturer is Eskayef Pharmaceuticals Limited, Bangladesh. The label includes directions for dispensing a medication guide, storage temperature, and safety warnings.*

FDA Label Image

82804-300-60 (Image 02)

Pregabalin 150 mg capsules label from Proficient Rx LP, containing 60 capsules. The label includes NDC 82804-300-60 and indicates the capsules are white hard gelatin printed with black ink. Manufactured by Eskayef Pharmaceuticals Limited in Bangladesh. Storage recommended at 20°-25°C (68°-77°F).*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph depicts the percent improvement in pain from baseline on the x-axis against the percent of patients improved on the y-axis. Four curves represent different doses of Pregabalin taken three times a day (200 mg, 100 mg, 25 mg) and a placebo group, showing comparative pain improvement percentages across the groups.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing percent improvement in pain from baseline to the percent of patients improved, showing two lines: one for Pregabalin 100 mg three times a day and one for placebo. The x-axis represents percent improvement in pain from >0 to 100, and the y-axis represents percent of patients improved from 0 to 100. The Pregabalin line consistently shows higher percentages of patients improved compared to placebo across the range of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo. The graph illustrates patient response to varied dosages of Pregabalin and placebo in pain reduction.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 200 mg three times a day, 100 mg three times a day, and placebo. The graph shows three lines indicating patient responses over a range of pain improvement percentages, highlighting differences between the Pregabalin doses and placebo.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph depicts decreasing percentages of patients improved as pain improvement increases, with the highest improvement rates for Pregabalin 100 mg and 50 mg doses compared to placebo.*

FDA Label Image

Figure 6 (Pregabalin 07)

Bar graph showing responder rates (%) for Pregabalin dosages across two studies, E1 and E3. Study E1 compares placebo and various dosages (50 mg/day to 600 mg/day) with increasing responder rates; Study E3 compares placebo with 600 mg/day given twice and thrice daily. The graph highlights dose response trends in responder rates.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph showing seizure reduction as median percentage change from baseline versus dose in mg/day for Pregabalin. Four studies are compared: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID, with dose points at 0, 150, 300, and 600 mg/day. Significant p-values are indicated for various dose levels.*

FDA Label Image

Figure 8 (Pregabalin 09)

A bar graph depicting responder rates (%) on the vertical axis, comparing placebo and two doses (2.5 mg/kg/day and 10 mg/kg/day) of Pregabalin. The graph shows responder rates of 22.6% for placebo with 93 subjects, 29.1% for 2.5 mg/kg/day with 103 subjects, and 40.6% for 10 mg/kg/day with 96 subjects.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for different doses of pregabalin and placebo. It compares daily doses of pregabalin at 600 mg, 450 mg, and 300 mg with placebo, showing trends of patient improvement across percent pain improvement from 0 to 100.*

FDA Label Image

Figure 10 (Pregabalin 11)

A Kaplan-Meier curve chart comparing Predgabalin and placebo over 180 days, showing the estimated percentage of subjects without LTR (Likely Treatment Response). The y-axis represents the estimated percentage of subjects without LTR from 0% to 100%, and the x-axis represents time in days. Pregabalin data is shown with a solid line, and placebo with a dashed line.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line graph comparing the percent of subjects improved from baseline to week 12 using the Brief Pain Coping Factor (BPCF) between Pregabalin and placebo groups. The x-axis represents percent improvement from 0% to 100%, and the y-axis represents percent of subjects improved. Two curves are shown: a solid line for Pregabalin and a dotted line for placebo.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line graph showing the percentage of subjects improved from baseline to week 16 using the Brief Overall Complaint Form (BOCF). The x-axis represents percent improvement from 0 to 100, while the y-axis indicates the percent of subjects improved from 0% to 100%. Two lines compare Pregabalin (solid line) and Placebo (dashed line) responses, illustrating higher improvement percentages for Pregabalin over Placebo across the range.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.